Related Experiment Video
Updated: May 1, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
11.3K
Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients
Yang Yang1, Deyang Kong, Chao Wang
1Therapeutic Centre of Kidney Diseases, First Affiliated Hospital of Beidaihe Sanatorium of Beijing Military Region , Qinhuangdao, Hebei Province , P.R. China .
Renal Failure
|March 27, 2014
Summary
Platelet factor 4/heparin (PF4/H) antibody testing predicts thrombosis risk in hemodialysis patients. Aspirin and clopidogrel effectively prevent thrombosis by inhibiting platelet activation, with aspirin being a cost-effective option.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Platelet factor 4/heparin (PF4/H) antibody detection is crucial for assessing thrombosis risk in hemodialysis (HD) patients.
- The mechanisms underlying thrombosis survival in PF4/H antibody-positive patients and effective preventive strategies remain unclear.
- Current preventive methods for thrombosis in HD patients lack confirmed efficacy.
Purpose of the Study:
- To evaluate the predictive value of PF4/H antibody detection for thrombosis risk in hemodialysis patients.
- To investigate the characteristics of PF4/H antibody-positive patients who survive thrombosis.
- To assess the efficacy of anti-platelet agents in preventing thrombosis in PF4/H antibody-positive patients.
Main Methods:
- A single-center, semi-randomized controlled study involving 157 patients.
- Patients were stratified based on PF4/H antibody status.
- Participants were randomly assigned to different anti-platelet agent regimens.
Main Results:
- PF4/H antibody-positive patients exhibited a significantly higher thrombosis incidence compared to antibody-negative patients.
- Survivors of thrombosis among PF4/H antibody-positive patients showed prolonged bleeding times and reduced platelet aggregation inhibition.
- Aspirin and clopidogrel demonstrated efficacy in reducing thrombosis incidence by inhibiting platelet activation in PF4/H antibody-positive individuals.
Conclusions:
- PF4/H antibody testing is a reliable predictor of thrombosis risk, with exceptions in patients possessing dysfunctional platelets.
- Aspirin and clopidogrel offer comparable effectiveness in preventing thrombosis in PF4/H antibody-positive patients.
- Aspirin is recommended due to its similar efficacy to clopidogrel and lower cost.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:22Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
01:25Hemodialysis I: Introduction
4.0K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
4.0K
01:24Hemodialysis II: Procedure and Complications
2.2K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
2.2K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689